Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer(†)

BACKGROUND: Everolimus synergistically enhances taxane-induced cytotoxicity in breast cancer cells in vitro and in vivo in addition to demonstrating a direct antiproliferative activity. We aim to determine pharmacodynamics changes and response of adding everolimus to standard neoadjuvant chemotherap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gonzalez-Angulo, A. M., Akcakanat, A., Liu, S., Green, M. C., Murray, J. L., Chen, H., Palla, S. L., Koenig, K. B., Brewster, A. M., Valero, V., Ibrahim, N. K., Moulder-Thompson, S., Litton, J. K., Tarco, E., Moore, J., Flores, P., Crawford, D., Dryden, M. J., Symmans, W. F., Sahin, A., Giordano, S. H., Pusztai, L., Do, K-A., Mills, G. B., Hortobagyi, G. N., Meric-Bernstam, F.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4037860/
https://ncbi.nlm.nih.gov/pubmed/24669015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu124
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares